Lanreotide Evidence Guide
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.
Our Take
Lanreotide (Somatuline) is FDA-approved for acromegaly and gastroenteropancreatic NETs, with Phase 3 data including the CLARINET trial showing significant PFS improvement in well-differentiated GEP-NETs. As a deep subcutaneous depot injection, it offers 28-day dosing convenience. A well-validated alternative to octreotide LAR with superior NET data.
- Best for
- Acromegaly, gastroenteropancreatic NETs, somatostatin analog pharmacology, GH/IGF-1 suppression
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 60-120mg deep subcutaneous every 28 days (autogel/depot)
Benefits and Evidence
- Acromegaly Biochemical Control: Level A, includes human evidence - Normalizes GH <=2.5 ng/mL and IGF-1 in approximately 50-65% of treatment-naive acromegaly patients. Extended dosing intervals (every 6-8 weeks) possible in well-controlled patients.
- GEP-NET Tumor Stabilization: Level A, includes human evidence - CLARINET trial showed significant prolongation of progression-free survival vs placebo in nonfunctioning GEP-NETs (median PFS not reached vs 18 months). Antiproliferative benefit independent of antisecretory effects.
- Gastrointestinal Side Effects: Level A, includes human evidence - Diarrhea, abdominal pain, and cholelithiasis are common side effects. Gallstones occur in 15-20% of patients on long-term therapy.
Side Effects and Warnings
- Diarrhea
- Abdominal pain
- Cholelithiasis
- Injection site reactions (nodule, pain)
- Nausea
- Flatulence
- Hyperglycemia
- Gallstones - baseline and periodic gallbladder ultrasound
Research Dosage References
- <strong>Deep subcutaneous injection</strong> - 60-120 mg - Every 28 days - Autogel formulation for acromegaly and GEP-NETs. Start at 90 mg. Adjust dose (60-120 mg) and interval based on response. Self-administration possible with training.
Mechanism of Action
Lanreotide provides sustained somatostatin receptor activation: 1. SSTR2-preferential binding: Primary affinity for somatostatin receptor subtype 2, with moderate affinity for SSTR5 and lower affinity for SSTR1, 3, and 4. 2. Supersaturated gel depot: Upon deep subcutaneous injection, lanreotide forms a drug depot at the injection site that slowly releases peptide over 4 weeks, maintaining therapeutic levels. 3. Antiproliferative effects: Directly inhibits tumor cell proliferation in GEP-NETs through SSTR2-mediated cell cycle arrest, and indirectly by reducing circulating growth factors. 4. Hormonal suppression: Inhibits GH secretion (acromegaly), serotonin and other bioactive peptides (carcinoid), and insulin/glucagon (insulinomas/glucagonomas).
Legal Status
FDA-approved for acromegaly and unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs. Available by prescription. Marketed as Somatuline Depot by Ipsen. Extended indication for carcinoid syndrome.
Primary Sources
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET). N Engl J Med, 2014.
- Lanreotide Autogel for acromegaly: integrated 5-year efficacy and safety data. J Clin Endocrinol Metab, 2014.
- Comparison of lanreotide and octreotide in the treatment of acromegaly. Pituitary, 2008.